お知らせ • May 11
ZeroStack Corp., Annual General Meeting, Jul 13, 2026 ZeroStack Corp., Annual General Meeting, Jul 13, 2026. Location: dorsey & whitney llp, 66 wellington street west, suite 3400, on m5k 1e6., toronto, Canada お知らせ • Jan 08
Flora Growth Corp. Announces Board and Committee Changes Flora Growth Corp. unanimously approved by written consent the appointment of (i) Mr. Larry Zeifman as a director of the Company, as a member of the audit committee of the Board (the "Audit Committee"), as a member of the compensation committee of the Board (the "Compensation Committee"), as a member of the nominating and corporate governance committee of the Board (the "Nominating Committee") and as Chair of the Audit Committee and (ii) Mr. Manfred Leventhal as Chair of the Nominating Committee. The Board has determined that Mr. Zeifman is an independent director, meets the applicable standards for Audit Committee service under both the Nasdaq Stock Market Rules and Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and meets the applicable standards for Compensation Committee service under the Nasdaq Stock Market Rules. Mr. Zeifman's appointment fills the vacancy on the Board, the Compensation Committee and the Nominating Committee which resulted from the passing of Harold Wolkin on August 25, 2025. お知らせ • Apr 17
Flora Growth Corp., Annual General Meeting, Jul 21, 2025 Flora Growth Corp., Annual General Meeting, Jul 21, 2025. Location: dorsey & whitney llp, 66 wellington street west, suite 3400, on m5k 1e6., toronto Canada お知らせ • Feb 12
Flora Growth Corp. Appoints Patrick Moloney as Head of Product Development for Its Accessory Brand, Vessel Flora Growth Corp. announced the appointment of Patrick Moloney as Head of Product Development for its accessory brand, Vessel. Mr. Moloney brings over two decades of product innovation and leadership experience, having held senior roles in product development at several globally recognized companies. His expertise in design and strategy will help drive Vessel's continued growth in the premium accessories market. Mr. Moloney's career highlights include serving as Design Manager on New Product Innovation at Dyson, where he was responsible for leading a team in developing consumer products. His experience in the highly competitive consumer goods sector was further honed during his tenure as Senior Manager of New Sciences at British American Tobacco, where he was tasked with creating next-generation product offerings. Most recently, as Chief Product Officer at InLab Ventures, Mr. Moloney led the development of innovative products and services across multiple industries, focusing on sustainability and user experience.Mr. Moloney is an inventor of over 300 patents who has brought to market iconic inventions, including the Dyson Supersonic Hairdryer and Dyson Airblade Tap, as well as developing foundational concepts for Dyson's floorcare range. At British American Tobacco, Mr. Moloney's contributions resulted in over 170 inventions and 120 patent filings, representing about 25% of British American Tobacco's total filings during his tenure.in his new role, Mr. Moloney will oversee Vessel's product development, leveraging his extensive experience to drive innovation, enhance product quality, and strengthen Vessel's market position. As the cannabis accessories market evolves, his appointment underscores Flora's commitment to providing consumers with the highest-quality products and elevating the Vessel brand. お知らせ • Oct 11
Flora Growth Corp. Appoints Manfred Ziegler as Managing Director Flora Growth Corp. announced the appointment of Dr. Manfred Ziegler as a Managing Director. Dr. Ziegler, a renowned figure in the pharmaceutical industry, brings decades o expertise, notably his leadership as Managing Director of CC Pharma and his pivotal role in the sale of CC Pharma to Tilray, one of the world's leading cannabis companies. With the appointment of Dr. Ziegler, Flora Growth is poised to accelerate its ambition to become one of the leading cannabis companies in Germany. His strategic leadership and proven ability to drive growth in complex markets will be instrumental as Flora expands its operations in Germany, targeting increased market share and a stronger foothold in Europe's rapidly evolving cannabis sector. Dr. Ziegler's tenure at CC Pharma marked a period of growth and strategic innovation. As Managing Director, he transformed the company into one of Europe's leading pharmaceutical distributors, with a robust portfolio and a significance presence in the European market. His leadership was instrument in the successful acquisition of CC Pharma by Tilray. The sale of CC Pharma to Tilray was a significant transaction in the cannabis and pharmaceutical sectors. This acquisition positioned Tilray as a key player in the European medical cannabis market, leveraging CC Pharma's established distribution network to expand its reach in the rapidly growing sector. Dr. Manfred Ziegler is a seasoned executive with over 30 years of experience in the pharmaceutical and healthcare sectors, recognized for his expertise in corporate restructuring and business transformation. Prior to his tenure at CC Pharma, Dr. Ziegler held leadership roles at several prominent companies, where he managed complex international operations and contributed to substantial revenue growth. His track record of strategic realignment and operational efficiency has made him a respected leader in the industry. In his role as Managing Director, Dr. Ziegler will work closely with Flora's executive team, providing insights and guidance on international distribution strategies, regulatory compliance, and market expansion. His understanding of the German market, combined with his experience in overseeing large- scale transactions, will be critical as Flora accelerates its growth plans and pursues opportunities in Europe. One of Dr. Ziegler's key objectives will be to spearhead the launch of the Company's parallel import business in Germany. Parallel importing involves purchasing pharmaceutical products from other EU countries where prices are lower, and then importing them into Germany to sell at competitive rates. This practice is highly regulated but provides an opportunity to reduce costs for consumers and increase Flora's market presence. Dr. Ziegler's vast experience in the pharmaceutical sector, particularly in navigating regulatory complexities and optimizing supply chains, will be critical in establishing Flora as a leader in this space, helping the company provide affordable, high-quality products to the German market. お知らせ • Sep 12
Flora Growth Corp. Announces Board Changes Flora Growth Corp. announced the appointment of Harold Wolkin as an independent director on its Board of Directors. In this role, Mr. Wolkin will also serve as a member of each of the Company's committees, including as Chair of the Audit Committee. Mr. Wolkin brings over 30 years of progressive experience in the finance sector, having held significant roles in investment banking, including positions at BMO Capital Markets and Dundee Capital Markets. His extensive background and expertise will be instrumental in guiding Flora's financial strategy and governance as the Company continues to expand its global operations. In addition to his new role at Flora, Mr. Wolkin currently serves on the boards of several publicly listed companies. He is the Audit Committee Chair at Baylin Technologies Inc, the Lead Independent Director and Audit Committee Chair at Cipher Pharmaceuticals, Chairman of Femto Technologies Inc. Mr. Wolkin has also made notable contributions to the financial community as a past President of the CFA Society Toronto, and he has been a member of the Chartered Financial Institute since 1980, holding the Chartered Financial Analyst (CFA) designation. Mr. Wolkin holds a Bachelor of Arts in Economics from York University and a Master of Arts in Economics and Finance from the University of Toronto. He is also a graduate and member of the Institute of Corporate Directors, further underscoring his commitment to excellence in corporate governance. Concurrently with Mr. Wolkin's appointment, Flora announced the appointment of Mr. Clifford Starke as Chairman of the Board of Directors. Mr. Starke is currently the Chief Executive Officer of the Company.